FDA Import Refusal 322-2557301-7/11/1 — Hikma Pharmaceuticals USA INC.

Hikma Pharmaceuticals USA INC. — FEI 1510690

The FDA refused shipment 322-2557301-7/11/1 from Hikma Pharmaceuticals USA INC. (United States) on Jan 12, 2022. The refused product falls under Drugs and Biologics — LINAGLIPTIN (ANTI-DIABETIC). Cited charges: 118,3280,472 This firm has 5 or more other import refusals on record.

Refusal details

Date
Jan 12, 2022
Country
United States
Product Category
Drugs and Biologics
Product Code
61PCA66 LINAGLIPTIN (ANTI-DIABETIC)
Charges
118,3280,472

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.